Tarix Orphan announced that the Food and Drug Administration (FDA) has granted Orphan Drug designation to TXA127 for the treatment of laminin-deficient congenital muscular dystrophy (LAMA2 MD or MDC1A).

Approximately 1 in 30,000 people develop early-onset LAMA2-related muscular dystrophy, which accounts for 30–40% of total cases of congenital muscular dystrophy.

RELATED: FDA Issues Complete Response Letter to Kyndrisa 

TXA127 previously received Orphan Drug designations for other muscular dystrophies including Duchenne’s muscular dystrophy (DMD) and limb girdle muscular dystrophy (LGMD).

Continue Reading

TXA127 is a pharmaceutical grade formulation of the naturally occurring peptide angiotensin (1-7).

For more information visit TarixOrphan.com.